Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1/2 2

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Lymphoma, Mantle-Cell 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma, Follicular 3Lymphoma, B-Cell, Marginal Zone 3Burkitt Lymphoma 3Waldenstrom Macroglobulinemia 2Sezary Syndrome 2Mycosis Fungoides 2Multiple Myeloma 2Lymphoma, Non-Hodgkin 2Lymphoma, Large-Cell, Immunoblastic 2Lymphoma, Large-Cell, Anaplastic 2Lymphoma, Extranodal NK-T-Cell 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Lymphocytic, Chronic, B-Cell 2Immunoblastic Lymphadenopathy 2Hodgkin Disease 2Anemia, Refractory, with Excess of Blasts 2Thrombocytopenia 1Thrombocythemia, Essential 1Stomach Neoplasms 1Sarcoma, Kaposi 1Sarcoma 1Rectal Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Polycythemia Vera 1Myelodysplastic Syndromes 1Melanoma 1Lymphoma, T-Cell, Peripheral 1

Interventions

Dexamethasone 133Lenalidomide 58Bortezomib 56Calcium Dobesilate 43Melphalan 41carfilzomib 38pomalidomide 36Cyclophosphamide 35daratumumab 23belantamab mafodotin 21Peripheral Blood Stem Cell Transplantation 17ixazomib 16dexamethasone acetate 13Filgrastim 13Bendamustine Hydrochloride 13fludarabine phosphate 12fludarabine 12dexamethasone 21-phosphate 12Tacrolimus 12auricularum 11Whole-Body Irradiation 11liposomal doxorubicin 10iberdomide 10Prednisone 10venetoclax 9selinexor 9Mycophenolic Acid 9pembrolizumab 8isatuximab 8Cyclosporine 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Multiple Myeloma × Gene Expression Profiling × Clear all
NCT01155583 2020-11-16

Low-Dose Azacitidine, Lenalidomide, and Low-Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma

Case Comprehensive Cancer Center

Phase 1/2 Completed
45 enrolled 20 charts
Plasma cell

Multiple Myeloma

NCT01212952 2020-04-17

Pomalidomide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

Mayo Clinic

Phase 1/2 Completed
50 enrolled 12 charts
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡